ProCE Banner Activity

Potential Drugs of Abuse as Antidepressants?

Slideset

This presentation on potential drugs of abuse as antidepressants reviews recent data on current drug development from a mechanism of action (MoA) perspective; how MoAs can affect risk–benefit ratio; MoA, efficacy, and adverse event data of new antidepressants and those under development.

Released: March 22, 2022

Share

Faculty

Alan F. Schatzberg

Alan F. Schatzberg, MD

Kenneth T. Norris, Jr., Professor
Department of Psychiatry and Behavioral Sciences
Stanford University
Stanford, California

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

Independent Educational Activity

Faculty Disclosure

Primary Author

Alan F. Schatzberg, MD

Kenneth T. Norris, Jr., Professor
Department of Psychiatry and Behavioral Sciences
Stanford University
Stanford, California

Alan F. Schatzberg, MD, has disclosed that he has received consulting fees from ANeuroTech, Axsome, Boehringer Ingelheim, Compass, Delpor, EMA Wellness, Janssen, Jazz, McKinsey, Myriad Genetics, NeuraWell, Otsuka, Owl Insights, Schwabe, Signant, Tris, and Vorso and has ownership interest in Alto, Corcept, Delpor, Epiodyne, Intersect ENT, Madrigal, Merck, Nesos, Owl Insights, Seattle Genetics, Titan, Vorso, and Xhale.